Avalo Therapeutics, Inc. has filed an 8-K report detailing the decision of two board members, Dr. Jonathan Goldman and Mitchell Chan, to not seek re-election at the upcoming 2026 Annual Meeting of Stockholders. Both members will continue to serve on the board until the meeting, and their decision is not attributed to any disagreements regarding the company's operations or policies. The board expressed gratitude for their contributions during their tenure. This administrative change is part of the company's ongoing governance practices and does not indicate any significant operational or strategic shifts. The company remains focused on its mission and objectives as it prepares for the annual meeting, where new board members may be elected to fill the vacancies. The filing is part of Avalo's compliance with SEC regulations, ensuring transparency in its governance processes.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.